Nancy Dianis is a Vice President and Director of Westat’s Clinical Trials Practice, which conducts clinical trials, epidemiologic research, global health projects, and international surveys in developing countries.
She serves on the Board of Directors for Westat’s subsidiaries in South Africa, Costa Rica, and Thailand. Most recently Ms. Dianis served as Westat’s principal investigator and corporate officer for the CDC Tuberculosis Trials Consortium and the DMID 20-0022: “Prospective, Duration-Randomized, Partially Blinded, Phase 2 Study of the Efficacy and Tolerability of Bedaquiline, Delatnanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients with MDR-TB” (DRAMATIC).
In addition, Ms. Dianis was the principal investigator for a 6-year NHLBI project for the Global Health Activities in Developing Countries to Combat Non-Communicable Chronic Cardiovascular and Pulmonary Diseases Administrative Coordinating Center and for the Tuberculosis Clinical Diagnostics Research Consortium with Johns Hopkins University.
Prior to joining Westat, Ms. Dianis served as a Director of Medical Nursing at Johns Hopkins Bayview. She also served as a Nursing Service Chief for the National Institutes of Health Clinical Center, where she was administratively responsible for 14 medical units and 200 staff. She collaborated with clinical directors from nine NIH institutes as well as the Pediatric Branch of NCI, and the National Center for Human Genome Research to anticipate and plan nursing resources for biomedical research protocols.
MS, Adult Primary Nurse Practitioner Program, University of Rochester
BS, Nursing, Illinois Wesleyan University